Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S254100, C514S255030, C544S372000, C544S374000, C544S393000, C544S400000
Reexamination Certificate
active
06906073
ABSTRACT:
The invention provides compounds of Formula (I):wherein: R1-R4, A, L, and X have any of the values defined in the specification that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use, and methods and intermediates useful for preparing them.
REFERENCES:
patent: 6339087 (2002-01-01), Gong et al.
patent: 0 903 349 (1999-03-01), None
patent: 5-92921 (1993-04-01), None
patent: 98/27081 (1998-06-01), None
patent: WO 99/65874 (1999-12-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/35452 (2000-06-01), None
patent: WO 00/35453 (2000-06-01), None
patent: WO 00/35454 (2000-06-01), None
Heath et al. J. Clin. Invest. vol. 99, p. 178-184 (1997).
Owen, Pulmonary Pharmacology & Therapeutics, vol. 14, p. 193-202 (2001).
Du Bois Daisy Joe
Kertesz Denis John
Sjogren Eric Brian
Smith David Bernard
Wang Beihan
Green Grant D.
Raymond Richard L.
Roche Palo Alto LLC
LandOfFree
Piperazine CCR-3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine CCR-3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine CCR-3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469436